YOLFTbeta
Alpha Cognition Inc

Alpha Cognition Inc

ACOG · NASDAQ · Healthcare / Biotechnology

8.30USD-0.26 (-3.04%)

Price History

Full chart

Market Stats

Previous Close8.56
Open8.53
Day Range8.17 – 8.60
52-Week Range4.50 – 10.14
Volume87.29K
Market Cap184.46M
P/E (TTM)0.00
Forward P/E26.88
EPS-0.96
Dividend Yield0.00%
Beta2.24
50-Day Avg8.86
200-Day Avg6.79

About

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Michael E. McFadden B.B.A.
  • Employees71
  • Headquarters1452 Hughes Street, Grapevine, TX, United States, 76051, USA
  • Websitehttps://www.alphacognition.com

Leadership

  • Mr. Michael E. McFadden B.B.A.CEO & Director · b. 1967
  • Mr. Kenneth Anthony Cawkell B.A., LL.B.Founder, Consultant, Corporate Secretary & Director · b. 1951
  • Mr. Henry H. Du CPAVP of Finance & Accounting and Interim CFO · b. 1979
  • Ms. Lauren D'Angelo M.B.A.Chief Operating Officer · b. 1978
  • Dr. Denis G. Kay M.Sc., Ph.D.Chief Scientific Officer · b. 1957
  • Mr. Timothy AyersHead of Compliance
  • Ms. Christine RevealVice President of Marketing & Commercial Strategy

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--0000010.22M
Cost of Revenue------81.22K1.92M
Gross Profit-------81.22K8.30M
Gross Margin-------81.26%
Operating Expense------11.78M30.97M
Operating Income-43.16K-129.24K-7.28M-14.74M-18.09M-9.62M-11.86M-22.66M
Operating Margin--------221.72%
EBITDA-43.16K-129.24K-6.30M-24.12M-15.92M-13.62M-14.37M-22.66M
EBITDA Margin--------221.72%
Net Income-43.16K-118.59K-7.39M-24.91M-16.28M-13.77M-14.64M-20.67M
Net Income Margin--------202.24%
R&D--5.97M10.16M11.85M5.00M3.92M1.87M
R&D as % of Total Revenue-------18.28%
Interest Expense--983.67K673.13K232.29K67.71K185.78K-

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--10.77M16.42M3.97M2.45M50.74M79.73M
Total Liabilities--10.75M4.91M5.74M7.16M9.27M17.20M
Total Equity--20.44K11.51M-1.77M-4.71M41.46M62.53M
Cash--7.57M14.40M2.80M1.49M48.55M66.11M
Total Debt--4.11M1.37M1.63M1.22M911.46K-
Net Debt---3.46M-13.03M-1.17M-274.20K-47.63M-66.11M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-47.36K-6.94M-12.59M-12.42M-8.73M-7.76M-20.38M
Investing Cash Flow--11.79K585.47K-6.55K--26.70K-293.49K
Financing Cash Flow590.17K7.50M18.96M33.30K8.16M54.85M38.21M
Capital Expenditure011.79K81.14K6.55K526.70K293.49K
Free Cash Flow-47.36K-6.96M-12.67M-12.42M-8.73M-7.78M-20.67M
Dividends Paid-0000--
FCF to OCF100.00%100.17%100.64%100.05%100.00%100.34%101.44%
Dividend Paid to FCF-0.00%0.00%0.00%0.00%--

Earnings

Report DateNov 30, 2021Apr 28, 2022Aug 25, 2022Nov 28, 2022Mar 8, 2023May 31, 2023Aug 23, 2023Nov 29, 2023May 15, 2024Aug 12, 2024Nov 15, 2024Mar 31, 2025May 15, 2025Aug 14, 2025Nov 13, 2025Mar 27, 2026May 14, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate--1.50-1.25-1.25-0.75-----1.00-1.00-0.48-0.58-0.46-0.43-0.35-0.39-0.39-0.33
EPS Actual-2.33-1.75-1.25-1.00-1.25-0.60-0.74-0.86-0.87-0.25-0.31-0.50-0.20-0.65-0.30-0.31-0.32-0.40-
Surprise--16.67%0.00%20.00%-66.67%----75.00%69.00%-4.17%65.52%-41.30%30.23%11.43%17.95%-2.56%-
Timing-After-hoursAfter-hoursAfter-hoursAfter-hours----After-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap184.46M
Enterprise Value144.45M
Trailing P/E0.00
Forward P/E26.88
Price / Sales12.09
Price / Book3.63
EPS-0.96
Book Value2.43
Revenue (TTM)15.26M
Gross Profit (TTM)13.79M
EBITDA-26.49M
Profit Margin-137.70%
Operating Margin-127.29%
Return on Equity-49.53%
Return on Assets-30.40%
Shares Outstanding21.78M
Shares Float11.49M
Beta2.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 18.00
  • Buy
    1

Ownership Breakdown

Institutions
56.12%
Insiders
5.13%
Retail / Other
38.75%

Top Institutional Holders

  • Opaleye Management Inc
    2.90M13.30%
  • Solas Capital Management LLC
    1.92M8.84%
  • Awm Investment Company Inc
    1.67M7.68%
  • Cable Car Capital LLC
    1.38M6.35%
  • Ikarian Capital, LLC
    1.06M4.85%
  • Sphera Funds Management Ltd.
    567.62K2.61%
  • Alyeska Investment Group, L.P.
    365.00K1.68%
  • BOOTHBAY FUND MANAGEMENT, LLC
    256.39K1.18%
  • Aristides Capital LLC
    218.51K1.00%
  • CANTOR FITZGERALD, L. P.
    188.63K0.87%
  • Citadel Advisors Llc
    97.55K0.45%
  • Villere St Denis J & Co Llc
    71.16K0.33%
  • Tudor Investment Corp Et AL
    61.60K0.28%
  • ACT Capital Management, LLC
    51.50K0.24%
  • Berkshire Asset Management Inc
    19.82K0.09%
  • Two Sigma Investments LLC
    18.83K0.09%
  • Geode Capital Management, LLC
    11.99K0.06%
  • NATIONAL BANK OF CANADA /FI/
    5.29K0.02%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    14.31K0.07%
  • Avantis US Small Cap Equity ETF
    4.19K0.02%

Stock Splits

  • Nov 5, 20241:25